Evidence map›Paper›PMID 32295632›Full record

ReviewBiology of sex differences2020

Sex differences in cancer mechanisms.

Joshua B Rubin, Joseph S Lagas, Lauren Broestl, Jasmin Sponagel, Nathan Rockwell, Gina Rhee, Sarah F Rosen, Si Chen, Robyn S Klein, Princess Imoukhuede and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Biology of sex differences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 201 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
201citing papers in PubMed, 5 pooled it
40.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

201 citing papers in PubMed, 5 syntheses or guidelines pooled it, 365 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

141 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Joshua B RubinDepartment of Pediatrics, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA. Rubin_j@wustl.edu.
Joseph S LagasDepartment of Pediatrics, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA.
Lauren BroestlDepartment of Pediatrics, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA.
Jasmin SponagelDepartment of Pediatrics, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA.
Nathan RockwellDepartment of Pediatrics, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA.
Gina RheeDepartment of Pediatrics, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA.
Sarah F RosenDepartment of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA.
Si ChenDepartment of Biomedical Engineering, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA.
Robyn S KleinDepartment of Neuroscience, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA.
Princess ImoukhuedeDepartment of Biomedical Engineering, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA.
Jingqin LuoDepartment of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA.
Washington University in St. Louis · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
West Nile Virus and host control of innate defensesU19AI083019 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL · 2009 to 2018
$22.5M
TAM Receptors and Virus InfectionR01AI101400 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI DIAMOND, MICHAEL S, KLEIN, ROBYN S. · 2012 to 2021
$5.8M
Neuroprotection and repair during West Nile Virus EncephalitisR01NS052632 · NINDS · WASHINGTON UNIVERSITY · PI KLEIN, ROBYN S. · 2005 to 2020
$5.0M
MOLECULAR BASIS FOR THE IMPACT OF SEX ON BRAIN TUMORIGENESISR01CA174737 · NCI · WASHINGTON UNIVERSITY · PI RUBIN, JOSHUA B · 2014 to 2024
$3.5M
NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA174737NIAID NIH HHS R01 AI101400NIAID NIH HHS U19 AI083019NIH HHS R01 AI101400NIH HHS R01 NS052632NINDS NIH HHS R01 NS052632
6 · The paper itself

Abstract

We now know that cancer is many different diseases, with great variation even within a single histological subtype. With the current emphasis on developing personalized approaches to cancer treatment, it is astonishing that we have not yet systematically incorporated the biology of sex differences into our paradigms for laboratory and clinical cancer research. While some sex differences in cancer arise through the actions of circulating sex hormones, other sex differences are independent of estrogen, testosterone, or progesterone levels. Instead, these differences are the result of sexual differentiation, a process that involves genetic and epigenetic mechanisms, in addition to acute sex hormone actions. Sexual differentiation begins with fertilization and continues beyond menopause. It affects virtually every body system, resulting in marked sex differences in such areas as growth, lifespan, metabolism, and immunity, all of which can impact on cancer progression, treatment response, and survival. These organismal level differences have correlates at the cellular level, and thus, males and females can fundamentally differ in their protections and vulnerabilities to cancer, from cellular transformation through all stages of progression, spread, and response to treatment. Our goal in this review is to cover some of the robust sex differences that exist in core cancer pathways and to make the case for inclusion of sex as a biological variable in all laboratory and clinical cancer research. We finish with a discussion of lab- and clinic-based experimental design that should be used when testing whether sex matters and the appropriate statistical models to apply in data analysis for rigorous evaluations of potential sex effects. It is our goal to facilitate the evaluation of sex differences in cancer in order to improve outcomes for all patients.

Indexed as

NeoplasmsSex CharacteristicsAnimalsCellular SenescenceEpigenomicsHumansNeovascularization, PathologicTumor Suppressor Protein p53Tumor Suppressor Protein p53AngiogenesisCancerEpigeneticsImmunityMetabolismp53SenescenceSex differencesTumor Suppressor

Identifiers

PMID32295632
PMCPMC7161126
OpenAlexW3016662185

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.